Investigation Of FDA Employee Misconduct Charges Returns to OIG
This article was originally published in The Tan Sheet
A "stronger appearance of impartiality, integrity" will result from returning investigative authority over allegations of FDA employee misconduct to the Department of Health and Human Services Office of Inspector General, a House Energy and Commerce Committee aide says
You may also be interested in...
The new Democratic-controlled House Energy and Commerce Committee initiated its first public inquiry into FDA Jan. 22, seeking documents relating to the oversight of conflicts of interest in the agency's contracting practices
FDA RETALIATION INVESTIGATIONS UNDER "INDEPENDENT" OUTSIDE PROCESS will be included in House legislation aimed at reforming FDA, House Commerce/oversight subcommittee Chairman Joe Barton (R-Tex.) promised in his opening statement during a Nov. 15 subcommittee hearing. "As this Congress moves forward on FDA reform...I will insist on an independent review process outside of FDA to handle cases" of alleged retaliation by the agency against industry, Barton said.
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.